These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

789 related items for PubMed ID: 20518584

  • 1. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC, Marcoux RM, Quilliam BJ.
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [Abstract] [Full Text] [Related]

  • 2. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT, Neill KK, Davis DA.
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV.
    J Manag Care Pharm; 2007 Apr; 13(9):799-806. PubMed ID: 18062731
    [Abstract] [Full Text] [Related]

  • 6. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.
    Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.
    Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779
    [Abstract] [Full Text] [Related]

  • 7. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC, Christofferson S, Humble CG, Wegner SE, Feaganes JR, Trygstad TK.
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [Abstract] [Full Text] [Related]

  • 8. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A, Seymour L, Tackett R, Perri M.
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [Abstract] [Full Text] [Related]

  • 9. Implementation of an opioid management initiative by a state Medicaid program.
    Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey P.
    J Manag Care Spec Pharm; 2014 May; 20(5):447-54. PubMed ID: 24761816
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM.
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M, Lin D, Lafeuille MH, Ghelerter I, Morrison L, Lefebvre P, Joshi K.
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP, Schaecher K, Cannon HE, Speckman M.
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [Abstract] [Full Text] [Related]

  • 20. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
    Martin C, Odell K, Cappelleri JC, Bancroft T, Halpern R, Sadosky A.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.